Abstract
Intestinal ischemia-reperfusion injury (IRI) is a potentially severe clinical syndrome after major surgical procedures. In addition to causing intestinal mucosa injury, intestinal IRI further damages distant organs, causing the severity of the condition in patients. So far, effective therapy for intestinal IRI is still absent, and the survival rate of the patients is low. Previous experimental studies have shown that some anesthetics can alleviate intestinal IRI and protect organs while exerting their pharmacological effects, indicating that reasonable perioperative anesthesia management may provide potential benefits for patients to avoid intestinal IRI. These meaningful findings drive scholars to investigate the mechanism of anesthetics in treating intestinal IRI in-depth to discuss the possible new clinical uses. In the present mini-review, we will introduce the protective effects of different anesthetics in intestinal IRI to help us enrich our knowledge in this area.
Introduction
Intestinal ischemia-reperfusion injury (IRI) is a potentially severe clinical syndrome of several major surgical procedures, including cardio-pulmonary bypass surgery, liver transplantation, bowel resection and transplantation, abdominal aortic aneurysm surgery, and strangulated hernias (; ; ). Intestinal IRI is a serial cascade of pathophysiologic changes of mucosal barrier failure, bacteria translocation, and inflammation caused by the disruption of blood and oxygen supply and the subsequent reperfusion of the intestine after arterial obstruction, venous thrombosis, and diffuse vasospasm (). The intestine is more sensitive to IRI, which damages the integrity of the intestinal mucosal barrier and may lead to bacterial translocation through the intestinal wall, peritonitis, and subsequent systemic inflammatory response syndrome (SIRS) (; ). Intestinal IRI can also cause damage to distant organs, especially acute lung injury (ALI), and may even lead to multiple organ dysfunction syndrome (MODS), endangering the patient’s life (; ). Therefore, how to attenuate intestinal IRI after major surgical procedures encourages scholars to focus on exploring effective and safe prevention and treatment methods. Although several therapeutic strategies for intestinal IRI have been reported so far, including energy therapy, anti-free radical therapy, anti-leukocyte adhesion therapy, glucocorticoids, and mesenchymal stem cells (MSCs) therapy, and even some miRNAs are considered new targets for the research and development of innovative drugs, there is no definite ideal treatment available for it (; ; ).
In recent years, many studies have demonstrated that some anesthetics attenuate operative stress during the perioperative period and have organ protective effects while exerting their pharmacological effects, particularly against IRI in various organs, attracting extensive attention and reflection (; ; ). In addition to ischemic preconditioning (IPC) and remote ischemic preconditioning (RIPC), reasonable anesthetic management in the perioperative period may be another strategy to supply some benefits for patients to avoid intestinal IRI. Some scholars have attempted to select specific anesthetics from gas anesthetics, intravenous anesthetics, analgesics, and sedatives to attenuate intestinal IRI and further explore the underlying mechanism. In particular, the research results of sevoflurane, propofol, dexmedetomidine, and remifentanil have provided experimental evidence of attenuation of intestinal IRI, suggesting that they may represent a prioritized selection of anesthetic management. In the present mini-review, we will introduce the protective effects of different anesthetics in intestinal IRI to help us enrich our knowledge in this area.
Sevoflurane
Sevoflurane is a widely used inhalation anesthetic in clinical practice, which has the advantage of inducing rapid and rapid resuscitation compared with other inhalation anesthetics (; ). Sevoflurane is potentially neurotoxic and may cause weak effects on cognitive function after a short or single exposure and cognitive dysfunction after prolonged or repeated exposure. It raises our concern about the potential neurotoxic effect of sevoflurane, particularly in brain development in childhood (). However, existing findings demonstrated that sevoflurane has the activity of anti-oxidative stress, anti-inflammation, and neuroprotective effects and also can attenuate IRI, for instance, cerebral IRI injury (; ; ). Hei and his research team first explore the protection effect of sevoflurane preconditioning on small intestinal IRI in Sprague-Dawley (SD) rats. In their study, the SD rats were first exposed to 2.3% sevoflurane for 1 h per day for 3 days. Subsequently, they clamped the rats’ superior mesenteric artery (SMA) for 75 min and then released the clamp to maintain reperfusion for 2 h. They found no difference in the survival rates between the rats treated with sevoflurane preconditioning or oxygen alone. However, a degree of intestine injury and Chiu’s scores of the rats treated with sevoflurane decreased obviously. Sevoflurane preconditioning also downregulated the myeloperoxidase (MPO) activities, ICAM-1 protein expression, and IL-6 concentrations, indicating sevoflurane possibly through inhibiting neutrophil sequestration and systemic inflammation to attenuate small intestinal IRI. They suggested that sevoflurane preconditioning may provide some benefits in alleviating postoperative intestinal ischemia and mortality (). They also confirmed that sevoflurane preconditioning protects SD rats from intestinal ischemia-reperfusion-induced ALI via inhibiting NADPH oxidase and the synergistic action between oxidative stress and mast cell activation in a subsequent study, which may have a positive meaning for the clinical treatment of IIR-mediated ALI (). Liu et al. have successively studied and reported on the effects of clinically relevant concentrations of sevoflurane in attenuating intestinal IRI. They first exposed the intestinal IRI rat models to 0.25, 0.5, and 1.0 minimum alveolar concentration (MAC) sevoflurane before, during, or after intestinal ischemia-reperfusion, respectively. They observed that 0.5 MAC sevoflurane can reduce epithelial apoptosis for protecting the intestinal mucosa without severe respiratory inhibition during ischemia-reperfusion. However, the protective effect can be partially reversed by phosphatidylinositol 3 kinases (PI3K) inhibitor LY294002, suggesting that sevoflurane inhibits intestinal mucosal epithelial apoptosis via the activation of the PI3K/Akt pathway (). In the subsequent research, they observed the changes in protein kinase C (PKC) and mitochondrial ATP-sensitive potassium channel (mKATP) in intestinal IRI rats treated with sevoflurane preconditioning, suggesting that the protecting effects of sevoflurane preconditioning on intestinal IRI was also dependent on the activation of PKC and mKATP (). Later, they found that sevoflurane preconditioning reversed the high expression of NF-κB P65 protein, proinflammatory cytokine tumor necrosis factor-α (TNF-a), and interleukin-6 (IL-6) and upregulated PPARγ protein in the intestinal mucosa of intestinal IRI rats, indicating that sevoflurane inhibits the intestinal inflammatory reaction via activation of the PPARγ/NF-κB pathway (). Notably, they compared the efficacy of sevoflurane preconditioning and IPC attenuating intestinal IRI while studying the potential mechanism (). The results of the histopathological test and Chiu’s scores showed both sevoflurane preconditioning and IPC attenuated intestinal injury in rats, indicating that sevoflurane preconditioning can provide similar anti-intestinal IRI effects as IPC. These findings provide valuable experimental evidence of clinically relevant concentrations of sevoflurane in attenuating intestinal IRI, which may have great translational potential in patients at risk of intestinal IRI.
Propofol
Propofol, as a commonly used short-acting intravenous anesthetic, has some advantages in the anesthetic management of the perioperative period, including fast onset of anesthesia, short recovery time, repeated administration, and antiemetic effect. Hence, propofol has been widely administered for the induction and maintenance of anesthesia so far (; ). Previous studies have shown that propofol also has anti-inflammatory, antioxidant, and immunomodulatory properties, contributing to its neuroprotective effects but even affecting the cancer prognosis (; ; ). Given the unique pharmacological effects of propofol, many scholars have investigated the effect of propofol on intestinal IRI. Liu et al. selected three propofol regimens to investigate the effect on intestinal mucosal injury after intestinal IRI. Wistar rats were treated with propofol at a sedative dose before, during, or after the intestinal IRI, respectively. The histological measurement of intestinal mucosal injury and Chiu’s scores showed that three different propofol treatment regimens significantly alleviated intestinal mucosal injury after intestinal IRI, especially propofol preconditioning displayed the best protective effect. Propofol preconditioning can inhibit the levels of lipid peroxidation product malondialdehyde (MDA) via attenuating nitric oxide (NO) and endothelin-1 (ET-1) production and stimulate an over-production of endogenous superoxide dismutase (SOD) activity in the intestinal mucosa, indicating that propofol attenuates intestinal IRI may be attributable to its antioxidant properties. They suggested that propofol preconditioning at a sedative dose provides a profound protective effect in intestinal IRI rats, and it is worth exploring the clinical translational potential of propofol in patients at risk for intestinal IRI following major cardiac surgery or for critical care (). In addition to inhibiting MDA in intestinal IRI rats, found that propofol can also inhibit the production of inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-a) and interleukin-6 (IL-6). They suggested that the anti-inflammatory and antioxidant properties may contribute to the protection of propofol in intestinal ischemia/reperfusion-induced liver injury. believed those properties also seem to be the crucial mediating mechanisms of propofol for efficiently preventing intestinal ischemia/reperfusion-induced lung injury. confirmed that the anti-inflammatory of propofol comes from downregulating the p38 MAPK/NF-κB signaling pathway to inhibit the production of inflammatory cytokines in intestinal IRI rats. observed propofol decreased the number of cell apoptosis in the intestinal tissue of intestinal IRI rats besides anti-inflammatory and antioxidant. attributed this anti-apoptotic effect of propofol preconditioning to its antioxidant property modulating the ceramide pathway. Some studies proved mucosal mast cell (IMMC) activation is critical in intestinal IRI by secreting many mediators to induce intestinal epithelial injury and integrity disruption. Propofol preconditioning can suppress IMMC activation, and it can explain why propofol can attenuate Intestinal IRI, restore intestinal epithelial cell integrity, and prevent intestinal IRI-induced lung injury in rodents and even pigs from other perspectives (; ; ; ). The above findings showed propofol may provide a meaningful anesthetic management regimen for preventing intestinal IRI and organ injury following major surgery and is worthy of a further clinical study to examine the clinical significance.
Dexmedetomidine
Dexmedetomidine (DEX) is a highly selective α2-adrenoceptor agonist with unique sedative and analgesic properties and widespread use in the perioperative period (). Previous studies have demonstrated that DEX also has anti-inflammatory and anti-apoptotic properties, allowing it to provide multiple organ-protective effects in animal models of IRI (; ). Zhang et al. compared the effects of different doses of DEX given 1 h before intestinal ischemia or 1 h after the beginning of reperfusion on the intestinal injury of rats. They found that DEX at 2.5 μg/kg/h has no beneficial effects before or after ischemia, while DEX at 10 μg/kg/h led to severe hemodynamic suppression. Only when DEX at 5 μg/kg/h was infusion before ischemia can decrease intestinal injury and rat mortality by inhibiting the inflammatory response and intestinal mucosal epithelial apoptosis via α2 adrenoreceptor activation. Notably, the dose of 5 μg/kg/h DEX used in rats is equal to approximately 0.8 μg/kg/h in humans, which is a safe dose to apply in cardiovascular surgery and the ICU. However, DEX lacks a protective effect after ischemia. They speculated that this ineffectiveness may due to the slow onset of dexmedetomidine, which reaches its effect approximately 15 min after intravenous administration (). Some scholars also suggested this ineffectiveness may be due to DEX not inhibiting JAK/STAT signaling after ischemia, and the JAK/STAT signaling regulates the signal transduction for various cytokines and growth factors in inflammation processes and plays a pivotal role in intestinal IRI (). Another study also demonstrated the intestinal protection of DEX preconditioning in intestinal IRI rats. The authors suggested that DEX has good free radical scavenging and antioxidant properties, anti-apoptotic effects, and anti-inflammatory effects during the progress of intestinal IRI (). further evaluated the protective effect of DEX’s anti-inflammatory on intestinal IRI-induced lung injury, and they suggested the inhibitory effect of DEX on cytokine production and the immune response in lung tissue via modulating the TLR4/MyD88 pathway may provide valuable and effective protection to intestinal IRI rats. suggested that the cannabinoid receptor CB2-mediated PI3K/Akt pathway is also involved in the function of DEX against lung injury in intestinal IRI rats. Interestingly, suggested that the anti-inflammatory effect of DEX contributes to attenuating early cognitive dysfunction induced by intestinal IRI mice, indicating that DEX may also provide some benefits in reducing the incidence of cognitive dysfunction. Some new protective mechanisms of DEX in intestinal IRI in animal models have been reported in recent years. DEX can attenuate intestinal I/R injury by decreasing ferroptosis and pyroptosis, enhancing mitophagy, promoting the mitochondrial localization of TERT, and microbiota-related mechanisms (; ; ; ; ). These findings provide new experimental evidence supporting the protective effect of DEX against intestinal IRI and a unique insight into the clinical use of DEX, which has positive significance for DEX administration in the perioperative period.
Remifentanil
Remifentanil is a short-acting opioid with high analgetic potency, widely used in intra-operative or postoperative analgesia. It also takes part in general anesthesia induction and maintenance as a component of total intravenous anesthesia (; ; ). Remifentanil can attenuate the IRI of organs through multiple mechanisms, such as anti-inflammatory, antioxidant, and anti-apoptotic signaling pathways, that have attracted the attention of scholars (). Some scholars have confirmed the protective effects of remifentanil on intestinal IRI in their studies. injected 1 μg/kg of remifentanil into C57BL/6J mice before clamping the SMA for 30 min and then 60 min of reperfusion. The tissue injury and lipid peroxidation of jejunum and ileum and systemic IL-6 were analyzed by histology, malondialdehyde (MDA), and ELISA, respectively. They found that remifentanil preconditioning can attenuate the intestinal IRI and inhibit lipid peroxidation and systemic inflammatory response, indicating that pre-treatment of remifentanil may bring potential benefits in the clinical prevention of intestinal IRI. used the rat models and the rat intestinal epithelial IEC-6 cells to evaluate the protective effects of remifentanil preconditioning. They found that remifentanil preconditioning attenuated intestinal injury in intestinal IRI rats and IEC-6 cell apoptosis after being subjected to oxygen and glucose deprivation (OGD), but naltrindole (a δ-OR selective antagonist) and CTOP (a μ-OR selective antagonist) can markedly attenuate these changes. They suggested that δ- and μ-opioid receptors may play a critical role in the protection against intestinal IRI of remifentanil preconditioning. Then, they proposed a new perspective to explain the mechanism of remifentanil preconditioning in protection against intestinal IRI in a recent study. They found that remifentanil preconditioning attenuated intestinal IRI by reducing oxidative and ER stress, and the PDIA3 gene played an essential role in this protection process, but p38MAPK inhibitor (SB203580) can suppress the PDIA3 expression and abolish the intestinal protection of remifentanil, indicating that remifentanil activates p38MAPK to PDIA3 expression for inhibiting intestinal IRI-induced oxidative and ER stress (). In addition to the anti-inflammatory and antioxidant activity, suggested that remifentanil preconditioning can also improve intestinal contractility in intestinal IRI rats, resulting in restoring dysfunction of intestinal motility induced by the IRI. Therefore, the protection mechanism of remifentanil in intestinal IRI may be multifactorial, and the exact mechanism still needs further elucidation.
Other anesthetics
Ketamine is often used for anesthesia, analgesia, and sedation, but its applications beyond anesthesia are involved in the treatment of addiction, depressive episodes, asthma, and even inhibit cancer growth (; ; ; ; ). In addition, ketamine can also protect various tissues from IRI (; ). Previous studies found that pre-treatment of ketamine can reduce inflammatory cell infiltration and intestinal injury in intestinal IRI rats (; ; ). Ketamine also has some anticoagulant and platelet anti-aggregation properties and can improve the intestinal transit delay, contributing to the protective effects of ketamine. suggested that an intact enteric nervous system seems to need in the protective action of ketamine in intestinal IRI rats. Parecoxib sodium is an injectable COX-2-specific inhibitor and usually used for postoperative analgesia (). Li et al. reported that parecoxib sodium also exerts protective effects in intestinal IRI rats. They found that parecoxib sodium preconditioning attenuated intestinal injury and increased the rat survival rate by inhibiting inflammation, oxidative stress, and apoptosis (). Moreover, observed that isoflurane has anti-inflammatory effects and can reduce intestinal epithelial damage and permeability in intestinal IRI rats, and combined with oxygen-supplementation will provide additional benefits in the attenuation of intestinal IRI, indicating that anesthetic management will bring substantial positive influence in a rodent model of intestinal IRI.
Summary and outlook
Intestinal IRI causes severe intestinal mucosa histopathological injury and further damage to distant organs, causing the severity of the condition in patients. Unfortunately, effective therapy for intestinal IRI is still absent, leading to a high rate of mortality. According to statistics, about 26% of patients unable to live for more than a year (). Exploring the protection against intestinal IRI of anesthetic management is very important for patients who will suffer major surgical procedures. The research on specific anesthetics introduced above indicates that pre-treatment of these agents confers protection against intestinal IRI and distant organ injury by their anti-inflammatory, anti-oxidant, and anti-apoptotic properties. Preconditioning with specific anesthetics may be advantageous in patients with intestinal IRI, providing a referable opinion for anesthetic management in the perioperative period. However, some limits of current studies need attention and to be discussed.
First, the existing exciting research results are mainly from preclinical studies, but heterogeneity and methodological quality of these research are still unavoidable limitations. Animal experiments serve as a basis for exploring the efficacy and potential mechanisms of the anesthetics in treating intestinal IRI (). The animals commonly used to build animal models of intestinal IRI include rodents, pigs, cats, and dogs (). Previous studies on intestinal IRI mainly employed rodent models (see Table 1). Compared to large animals, rodents have the advantage of low cost, rapid reproduction rate, number of available and well-established models. summarized the establishment methods of the intestinal IRI rat model from strains, gender, age, weight, anesthesia, surgical details, ischemia and reperfusion time, and perioperative care in their published review. They realized that building a uniform standard for the intestinal IRI rat model would provide a reliable basis for the horizontal comparison of mechanism research. However, there are difficulties in surgery and a high mortality rate in the procedure of building IRI rodent models. In addition, the pathological and physiological changes of the rodent models’ intestinal tract differ to some extent from those in humans. Some scholars employed big animals to build the IRI animal models because it may be easier to develop safe preclinical protocols directly transferable to humans using those animals. For example, pigs are considered the ideal model for human intestinal IRI research because of their approximate morphology and function of human intestines. The bigger size of pigs is the ease of surgical manipulation. Scholars can temporarily occlude the smaller vessels within the mesentery without compromising the integrity and then reperfusion to cause intestinal IRI in pigs. However, the experimental costs, feeding management, and the number of models also limit the conduct of related experiments on intestinal IRI pig models. In addition to the animal models, the appropriate model-making method is critical to experimental design. classified the intestinal IRI modeling methods as complete vascular occlusion (SMA ligation and SMA embolization), low-flow ischemia, and segmental mesenteric vascular occlusion. They also compared the advantages and disadvantages of these methods in their published review. They suggested that the mesenteric vascular occlusion model of intestinal ischemia may be the prioritized modeling method because it can be readily performed in large animals (e.g., pigs) and rodents. Given current intestinal IRI animal experiments still lack optimal choices in animal species and modeling methods, the methodologic of the preclinical studies about anesthetics still needs to be further well-designed before clinical implication.
TABLE 1
| Anesthetics | Dose | Animal species | IRI modeling method | References |
|---|---|---|---|---|
| Sevoflurane | 2.3% | SD rat | 75 min SMA occlusion followed by 120 min reperfusion | , |
| Sevoflurane | 0.5, 1.0, and 2.0% | SD rat | 60 min SMA occlusion followed by 120 min reperfusion | , , |
| Propofol | 50 mg/kg | Wistar rats | 60 min SMA occlusion followed by 180 min reperfusion | , |
| Propofol | 10 mg/kg | Wistar rats | 30 min SMA occlusion followed by 120 min reperfusion | |
| Propofol | 60 mg/kg | Wistar rats | 45 min SMA occlusion followed by 240 min reperfusion | |
| Propofol | 50 mg/kg | SD rats | 45 min SMA occlusion followed by 90 min reperfusion | |
| Propofol | 60 mg/kg | SD rats | 60 min SMA occlusion followed by 120 min reperfusion | |
| Propofol | 50 mg/kg | SD rats | 75 min SMA occlusion followed by 120 min reperfusion | , |
| Propofol | 10 mg/kg/h | miniature pigs | 120 min SMA occlusion followed by 240 min reperfusion | |
| Dexmedetomidine | 2.5, 5, and 10 μg/kg/h | SD rats | 60 min SMA occlusion followed by 120 min reperfusion | |
| Dexmedetomidine | 10, 20, and 50 μg/kg | Wistar rats | 60 min SMA occlusion followed by 120 min reperfusion | |
| Dexmedetomidine | 50 μg | Wistar rats | 60 min SMA occlusion followed by reperfusion | |
| Dexmedetomidine | 2.5 and 5.0 μg/kg/h | SD rats | 60 min SMA occlusion followed by 120 min reperfusion | , |
| Dexmedetomidine | 5.0 μg/kg/h | SD rats | 60 min SMA occlusion followed by 120 min reperfusion | |
| Dexmedetomidine | 50 μg/kg | C57BL/6J mice | 45 min SMA occlusion followed by 24 h reperfusion | |
| Dexmedetomidine | 10 and 100 μg/kg | Wistar rats | 60 min SMA occlusion followed by 60 min reperfusion | |
| Dexmedetomidine | 400 μg/kg | C57BL/6 mice | 60 min SMA occlusion followed by 180 min reperfusion | |
| Remifentanil | 1.0 μg/kg | C57BL/6 mice | 30 min SMA occlusion followed by 60 min reperfusion | |
| Remifentanil | 0.1, 0.2, 0.6, and 1.0 μg/kg | SD rats | 60 min SMA occlusion followed by 120 min reperfusion | |
| Remifentanil | 1.0 μg/kg | C57BL/6 mice | 45 min SMA occlusion followed by 240 min reperfusion | |
| Remifentanil | 2.0 μg/kg/min | Wistar rats | 30 min SMA occlusion followed by 180 min reperfusion | |
| Ketamine | 100 mg/kg | Wistar rats | 45 min SMA occlusion followed by 60 min or 24 h reperfusion | |
| Ketamine | 6.25, 12.5, 50, and 100 mg/kg | Wistar rats | 30 min SMA occlusion followed by 60 min reperfusion | |
| Ketamine | 50 mg/kg | Wistar rats | 30 min SMA occlusion followed by 60 min reperfusion | |
| Parecoxib sodium | 10 and 20 mg/kg | SD rats | 60 min SMA occlusion followed by 120 min reperfusion | |
| Isoflurane | induction with 5% and maintenance with 1.5%–1.75% at 1 L/min | SD rats | 60 min SMA occlusion followed by 60 min reperfusion |
Literature examples of anesthetic application in Intestinal IRI animal models.
Second, the dosage of anesthetics in most intestinal IRI animal experiments is clinically relevant concentration, but there are growing concerns about the safety of anesthetic use. It is well-known that the neurotoxicity of anesthetics may inhibit the development of children’s nervous systems, weaken memory and learning functions, cause postoperative delirium, and even induce long-term cognitive dysfunction (; ; ; ; ). Research has confirmed that long-term exposure to sevoflurane in young animals could lead to a 50-fold increase in the rate of neuroapoptosis (). Some scholars suggested that anesthetic-induced neuroapoptosis is the leading cause of neurotoxicity, and exposure to anesthetics can cause neuroapoptosis through several different molecular mechanisms. For example, sevoflurane induces neuroapoptosis through the brain-derived neurotrophic factor (BDNF)-modulated apoptotic cascade, mitochondria-mediated apoptosis, death receptor signaling, intracellular ROS, and intracellular calcium homeostasis (). Other evidence has emerged that anesthetics can also induce neuroinflammation, impair hippocampal synaptic plasticity, and cause neurodegenerative changes, indicating the possible detrimental effects of anesthetics on both the young developing and the elderly aging brain (; ; ). Still, some experimental evidence of potential neuroprotective effects has been reported, making it somewhat equivocal. Therefore, further preclinical research is needed to enrich our understanding of anesthetics. In addition, it usually combines several anesthetics rather than a single anesthetic in perioperative anesthesia management, especially major surgeries and time-consuming surgeries. For instance, dexmedetomidine combined with propofol may decrease the demand doses and side effects of sedation (; ). We suggest that researchers pay attention to the adverse risks of anesthesia regimens when exploring the potential beneficial effects of synergistic use of anesthetics on intestinal IRI treatment. Developing appropriate anesthesia plans based on the patient’s condition is essential for achieving safe medication.
Third, we have learned that pre-treatment of specific anesthetics may provide outstanding protection effects for intestinal IRI and ALI from the introduced research in this review. Most studies confirmed that antioxidation, anti-inflammation, and anti-apoptotic are possible mechanisms of these protection effects. In recent years, scholars have also found that anesthetics regulate ferroptosis, pyroptosis, mitophagy, and gut microbiota to protect the intestinal mucosa (Figure 1). However, the exact mechanism of intestinal IRI is still unclear (). Intestinal IRI causes injury to multiple extraintestinal organs and is a multi-step process involving intestinal flora disturbance, bacterial translocation, endotoxin release, and multiple signaling pathways are involved (; ; ). Some scholars are also committed to revealing the pathological mechanisms of intestinal IRI from new perspectives. Non-coding RNAs, extracellular vesicles (EVs), intestinal microbiota derivatives, complement activation, and neutrophil extracellular traps play essential roles in the pathogenesis of intestinal IRI (; ; ; ; ). These findings will also further drive scholars to explore the mechanism of anesthetics to protect against intestinal IRI and help refine our knowledge in this aspect.
FIGURE 1
In a word, our review shows the beneficial effects of anesthetics on intestinal IRI, indicating that reasonable anesthetic management in the perioperative period may be an important strategy for avoiding intestinal IRI in major surgical procedures. Although current related research is still focused on preclinical studies, we should encourage further research efforts in this direction.
Statements
Author contributions
ZH: Writing–original draft. YB: Writing–original draft. YiC: Writing–original draft. YeC: Writing–original draft. YJ: Writing–original draft, Writing–review and editing. JZ: Writing–review and editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the grants from Research project of the Science and Technology Department of Sichuan province (2021YJ0217), the grants from the National Natural Science Foundation of China (No. 81873930), Sichuan Science and Technology Program (No. 2022YFS0615 and 2022YFS0632), Luzhou Science and Technology Program (No. 2023SYF099).
Acknowledgments
The authors also express their sincere thanks to Dr. Yuan Yi, Ms. Zunzhen Zhou for their helpful assistance.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AbboudB.DaherR.BoujaoudeJ. (2008). Acute mesenteric ischemia after cardio-pulmonary bypass surgery. World J. Gastroenterol.14, 5361–5370. 10.3748/wjg.14.5361
2
AdegbolaA.GritsenkoK.MedranoE. M. (2023). Perioperative use of ketamine. Curr. Pain Headache Rep.27, 445–448. 10.1007/s11916-023-01128-z
3
AkbariG. (2020). Emerging roles of microRNAs in intestinal ischemia/reperfusion-induced injury: a review. J. Physiol. Biochem.76, 525–537. 10.1007/s13105-020-00772-y
4
ÁlvarezP.TapiaL.MardonesL. A.PedemonteJ. C.FaríasJ. G.CastilloR. L. (2014). Cellular mechanisms against ischemia reperfusion injury induced by the use of anesthetic pharmacological agents. Chem. Biol. Interact.218, 89–98. 10.1016/j.cbi.2014.04.019
5
BianW. Y.ChenY. P.XuB.TangJ. (2021). Pretreatment with propofol reduces pulmonary injury in a pig model of intestinal ischemia-reperfusion via suppressing the high-mobility group box 1 protein (HMGB1)/Toll-Like receptor 4 (TLR4)/Protein kinase R (PKR) signaling pathway. Med. Sci. Monit.27, e930478. 10.12659/MSM.930478
6
CaiQ.LiuG.HuangL.GuanY.WeiH.DouZ.et al (2022). The role of dexmedetomidine in tumor-progressive factors in the perioperative period and cancer recurrence: a narrative review. Drug Des. Devel Ther.16, 2161–2175. 10.2147/DDDT.S358042
7
CaiY.XuH.YanJ.ZhangL.LuY. (2014). Molecular targets and mechanism of action of dexmedetomidine in treatment of ischemia/reperfusion injury. Mol. Med. Rep.9, 1542–1550. 10.3892/mmr.2014.2034
8
CámaraC. R.GuzmánF. J.BarreraE. A.CabelloA. J.GarciaA.FernándezN. E.et al (2008). Ketamine anesthesia reduces intestinal ischemia/reperfusion injury in rats. World J. Gastroenterol.14, 5192–5196. 10.3748/wjg.14.5192
9
CheerS. M.GoaK. L. (2023). Parecoxib (parecoxib sodium). Drugs61, 1133–1141. 10.2165/00003495-200161080-00010
10
ChenK.ShaoL. H.WangF.ShenX. F.XiaX. F.KangX.et al (2021b). Netting gut disease: neutrophil extracellular trap in intestinal pathology. Oxid. Med. Cell. Longev.2021, 5541222. 10.1155/2021/5541222
11
ChenM.YanX. T.YeL.TangJ. J.ZhangZ. Z.HeX. H. (2020a). Dexmedetomidine ameliorates lung injury induced by intestinal ischemia/reperfusion by upregulating cannabinoid receptor 2, followed by the activation of the phosphatidylinositol 3-kinase/akt pathway. Oxid. Med. Cell. Longev.2020, 6120194. 10.1155/2020/6120194
12
ChenX. D.ZhaoJ.YanZ.ZhouB. W.HuangW. F.LiuW. F.et al (2020b). Isolation of extracellular vesicles from intestinal tissue in a mouse model of intestinal ischemia/reperfusion injury. Biotechniques68, 257–262. 10.2144/btn-2019-0159
13
ChenY.PuW.MaswikitiE. P.TaoP.LiX.WangD.et al (2021a). Intestinal congestion and reperfusion injury: damage caused to the intestinal tract and distal organs. Biosci. Rep.41, BSR20211560. 10.1042/BSR20211560
14
ChengJ.WeiZ.LiuX.LiX.YuanZ.ZhengJ.et al (2013). The role of intestinal mucosa injury induced by intra-abdominal hypertension in the development of abdominal compartment syndrome and multiple organ dysfunction syndrome. Crit. Care17, R283. 10.1186/cc13146
15
ChoS. S.RudloffI.BergerP. J.IrwinM. G.NoldM. F.ChengW.et al (2013). Remifentanil ameliorates intestinal ischemia-reperfusion injury. BMC Gastroenterol.13, 69. 10.1186/1471-230X-13-69
16
ClarysseM.AccarieA.FarréR.CanovaiE.MonbaliuD.GunstJ.et al (2023). Protective effect of oxygen and isoflurane in rodent model of intestinal ischemia-reperfusion injury. Int. J. Mol. Sci.24, 2587. 10.3390/ijms24032587
17
CollardC. D.GelmanS. (2001). Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology94, 1133–1138. 10.1097/00000542-200106000-00030
18
DengF.HuJ. J.LinZ. B.SunQ. S.MinY.ZhaoB. C.et al (2023). Gut microbe-derived milnacipran enhances tolerance to gut ischemia/reperfusion injury. Cell. Rep. Med.4, 100979. 10.1016/j.xcrm.2023.100979
19
DongY. H.HuJ. J.DengF.ChenX. D.LiC.LiuK. X.et al (2022). Use of dexmedetomidine to alleviate intestinal ischemia-reperfusion injury via intestinal microbiota modulation in mice. Ann. Transl. Med.10, 1161. 10.21037/atm-22-824
20
DuffyC. M.MattaB. F. (2000). Sevoflurane and anesthesia for neurosurgery: a review. J. Neurosurg. Anesthesiol.12, 128–140. 10.1097/00008506-200004000-00012
21
ElbakryA. E.IbrahimE. (2017). Propofol-dexmedetomidine versus propofol-remifentanil conscious sedation for awake craniotomy during epilepsy surgery. Minerva Anestesiol.83, 1248–1254. 10.23736/S0375-9393.17.11873-0
22
ErturkE. (2014). Ischemia-reperfusion injury and volatile anesthetics. Biomed. Res. Int.2014, 526301. 10.1155/2014/526301
23
GanX.SuG.ZhaoW.HuangP.LuoG.HeiZ. (2013). The mechanism of sevoflurane preconditioning-induced protections against small intestinal ischemia reperfusion injury is independent of mast cell in rats. Mediat. Inflamm.2013, 378703. 10.1155/2013/378703
24
GanX.XingD.SuG.LiS.LuoC.IrwinM. G.et al (2015). Propofol attenuates small intestinal ischemia reperfusion injury through inhibiting NADPH oxidase mediated mast cell activation. Oxid. Med. Cell. Longev.2015, 167014. 10.1155/2015/167014
25
GaoX.MiY.GuoN.LuanJ.XuH.HuZ.et al (2020). The mechanism of propofol in cancer development: an updated review. Asia Pac J. Clin. Oncol.16, e3–e11. 10.1111/ajco.13301
26
GonzalezL. M.MoeserA. J.BlikslagerA. T. (2015). Animal models of ischemia-reperfusion-induced intestinal injury: progress and promise for translational research. Am. J. Physiol. Gastrointest. Liver Physiol.308, G63–G75. 10.1152/ajpgi.00112.2013
27
GrapeS.KirkhamK. R.FrauenknechtJ.AlbrechtE. (2019). Intra-operative analgesia with remifentanil vs. dexmedetomidine: a systematic review and meta-analysis with trial sequential analysisAnaesthesia74, 793–800. 10.1111/anae.14657
28
Guzmán-De La GarzaF. J.Cámara-LemarroyC. R.Ballesteros-ElizondoR. G.Alarcón-GalvánG.Cordero-PérezP.Fernández-GarzaN. E. (2010a). Ketamine reduces intestinal injury and inflammatory cell infiltration after ischemia/reperfusion in rats. Surg. Today40, 1055–1062. 10.1007/s00595-009-4177-4
29
Guzmán-de la GarzaF. J.Cámara-LemarroyC. R.Ballesteros-ElizondoR. G.Alarcón-GalvánG.Cordero-PérezP.Fernández-GarzaN. E. (2010b). Ketamine and the myenteric plexus in intestinal ischemia/reperfusion injury. Dig. Dis. Sci.55, 1878–1885. 10.1007/s10620-009-0976-0
30
HouM.ChenF.HeY.TanZ.HanX.ShiY.et al (2023). Dexmedetomidine against intestinal ischemia/reperfusion injury: a systematic review and meta-analysis of preclinical studies. Eur. J. Pharmacol.959, 176090. 10.1016/j.ejphar.2023.176090
31
HuQ.LiuX. M.LiuZ. R.LiuZ. Y.ZhangH. G.ZhangQ.et al (2022). Dexmedetomidine reduces enteric glial cell injury induced by intestinal ischaemia-reperfusion injury through mitochondrial localization of TERT. J. Cell. Mol. Med.26, 2594–2606. 10.1111/jcmm.17261
32
Ivan Ezquerra-RomanoI.LawnW.KrupitskyE.MorganC. J. A. (2018). Ketamine for the treatment of addiction: evidence and potential mechanisms. Neuropharmacology142, 72–82. 10.1016/j.neuropharm.2018.01.017
33
JohnsonS. C.PanA.LiL.SedenskyM.MorganP. (2019). Neurotoxicity of anesthetics: mechanisms and meaning from mouse intervention studies. Neurotoxicol Teratol.71, 22–31. 10.1016/j.ntt.2018.11.004
34
JungwirthB.ZieglgänsbergerW.KochsE.RammesG. (2009). Anesthesia and postoperative cognitive dysfunction (POCD). Mini Rev. Med. Chem.9, 1568–1579. 10.2174/138955709791012229
35
KangE.BergD. A.FurmanskiO.JacksonW. M.RyuY. K.GrayC. D.et al (2017). Neurogenesis and developmental anesthetic neurotoxicity. Neurotoxicol Teratol.60, 33–39. 10.1016/j.ntt.2016.10.001
36
KaplanN.YagmurdurH.KilincK.BaltaciB.TezelS. (2007). The protective effects of intravenous anesthetics and verapamil in gut ischemia/reperfusion-induced liver injury. Anesth. Analg.105, 1371–1378. 10.1213/01.ane.0000284696.99629.3a
37
KotaniY.ShimazawaM.YoshimuraS.IwamaT.HaraH. (2008). The experimental and clinical pharmacology of propofol, an anesthetic agent with neuroprotective properties. CNS Neurosci. Ther.14, 95–106. 10.1111/j.1527-3458.2008.00043.x
38
LiG.ZhangY.FanZ. (2021b). Cellular signal transduction pathways involved in acute lung injury induced by intestinal ischemia-reperfusion. Oxid. Med. Cell. Longev.2021, 9985701. 10.1155/2021/9985701
39
LiG.ZhouJ.WeiJ.LiuB. (2022a). Dexmedetomidine ameliorated cognitive dysfunction induced by intestinal ischemia reperfusion in mice with possible relation to the anti-inflammatory effect through the locus coeruleus norepinephrine system. Neurochem. Res.47, 3440–3453. 10.1007/s11064-022-03706-w
40
LiJ.HuangJ.ZhangR.LinY.ChenQ.GanX. (2022b). Pretreatment with propofol restores intestinal epithelial cells integrity disrupted by mast cell degranulation in vitro. Physiol. Res.71, 849–858. 10.33549/physiolres.934933
41
LiL.ShuF.WangX. Q.WangF.CaiL.ZhaoX.et al (2021a). Propofol alleviates intestinal ischemia/reperfusion injury in rats through p38 MAPK/NF-κB signaling pathway. Eur. Rev. Med. Pharmacol. Sci.25, 1574–1581. 10.26355/eurrev_202102_24867
42
LiM.ZhengZ. (2021). Protective effect of parecoxib sodium against ischemia reperfusion-induced intestinal injury. Mol. Med. Rep.24, 776. 10.3892/mmr.2021.12416
43
LiX.WangJ.SongX.WuH.GuoP.JinZ.et al (2018). Ketamine ameliorates ischemia-reperfusion injury after liver autotransplantation by suppressing activation of Kupffer cells in rats. Can. J. Physiol. Pharmacol.96, 886–892. 10.1139/cjpp-2018-0046
44
LiY.CaoY.XiaoJ.ShangJ.TanQ.PingF.et al (2020). Inhibitor of apoptosis-stimulating protein of p53 inhibits ferroptosis and alleviates intestinal ischemia/reperfusion-induced acute lung injury. Cell. Death Differ.27, 2635–2650. 10.1038/s41418-020-0528-x
45
LiangT. Y.PengS. Y.MaM.LiH. Y.WangZ.ChenG. (2021). Protective effects of sevoflurane in cerebral ischemia reperfusion injury: a narrative review. Med. Gas. Res.11, 152–154. 10.4103/2045-9912.318860
46
LiaoS.LuoJ.KadierT.DingK.ChenR.MengQ. (2022). Mitochondrial DNA release contributes to intestinal ischemia/reperfusion injury. Front. Pharmacol.13, 854994. 10.3389/fphar.2022.854994
47
LiuC.DingR.HuangW.MiaoL.LiJ.LiY. (2020). Sevoflurane protects against intestinal ischemia-reperfusion injury by activating peroxisome proliferator-activated receptor gamma/nuclear factor-κb pathway in rats. Pharmacology105, 231–242. 10.1159/000503727
48
LiuC.LiuY.ShenZ.MiaoL.ZhangK.WangF.et al (2015a). Sevoflurane preconditioning reduces intestinal ischemia-reperfusion injury: role of protein kinase C and mitochondrial ATP-sensitive potassium channel. PLoS One10, e0141426. 10.1371/journal.pone.0141426
49
LiuC.ShenZ.LiuY.PengJ.MiaoL.ZengW.et al (2015b). Sevoflurane protects against intestinal ischemia-reperfusion injury partly by phosphatidylinositol 3 kinases/Akt pathway in rats. Surgery157, 924–933. 10.1016/j.surg.2014.12.013
50
LiuK. X.ChenS. Q.HuangW. Q.LiY. S.IrwinM. G.XiaZ. (2008). Propofol pretreatment reduces ceramide production and attenuates intestinal mucosal apoptosis induced by intestinal ischemia/reperfusion in rats. Anesth. Analg.107, 1884–1891. 10.1213/ane.0b013e3181884bbf
51
LiuK. X.RinneT.HeW.WangF.XiaZ. (2007). Propofol attenuates intestinal mucosa injury induced by intestinal ischemia-reperfusion in the rat. Can. J. Anaesth.54, 366–374. 10.1007/BF03022659
52
LiuX.LengY.LvX.LvJ.ZhangM.ShiY. (2021). Dexmedetomidine inhibits endoplasmic reticulum stress to suppress pyroptosis of hypoxia/reoxygenation-induced intestinal epithelial cells via activating the SIRT1 expression. J. Bioenerg. Biomembr.53, 655–664. 10.1007/s10863-021-09922-3
53
LundströmS.TwycrossR.MihalyoM.WilcockA. (2010). Propofol. J. Pain Symptom Manage.40, 466–470. 10.1016/j.jpainsymman.2010.07.001
54
LuoC.YuanD.ZhaoW.ChenH.LuoG.SuG.et al (2015). Sevoflurane ameliorates intestinal ischemia-reperfusion-induced lung injury by inhibiting the synergistic action between mast cell activation and oxidative stress. Mol. Med. Rep.12, 1082–1090. 10.3892/mmr.2015.3527
55
LyuN.LiX. (2023). Sevoflurane postconditioning attenuates cerebral ischemia-reperfusion injury by inhibiting SP1/ACSL4-mediated ferroptosis. Hum. Exp. Toxicol.42, 9603271231160477. 10.1177/09603271231160477
56
MarikP. E. (2005). Propofol: an immunomodulating agent. Pharmacotherapy25, 28S-33S–33S. 10.1592/phco.2005.25.5_part_2.28s
57
MasonK. P.ParkR. S.SullivanC. A.LukovitsK.HalpinE. M.ImbresciaS. T.et al (2021). The synergistic effect of dexmedetomidine on propofol for paediatric deep sedation: a randomised trial. Eur. J. Anaesthesiol.38, 541–547. 10.1097/EJA.0000000000001350
58
McCannM. E.SorianoS. G. (2019). Does general anesthesia affect neurodevelopment in infants and children?BMJ367, l6459. 10.1136/bmj.l6459
59
MihaljevićS.PavlovićM.ReinerK.ĆaćićM. (2020). Therapeutic mechanisms of ketamine. Psychiatr. Danub32 (3-4), 325–333. 10.24869/psyd.2020.325
60
MotayagheniN.PhanS.EshraghiC.NozariA.AtalaA. (2017). A review of anesthetic effects on renal function: potential organ protection. Am. J. Nephrol.46, 380–389. 10.1159/000482014
61
NickkholghA.ContinP.Abu-ElmagdK.GolrizM.GotthardtD.MorathC.et al (2013). Intestinal transplantation: review of operative techniques. Clin. Transpl.27, 56–65. 10.1111/ctr.12190
62
NowackaA.BorczykM. (2019). Ketamine applications beyond anesthesia - a literature review. Eur. J. Pharmacol.860, 172547. 10.1016/j.ejphar.2019.172547
63
RenW.MatsusakiT.Abugri OsmanB.MorimatsuH. (2022). Association between the remifentanil dose during anesthesia and postoperative pain. Acta Med. Okayama76, 187–193. 10.18926/AMO/63413
64
RitterP.FindeisH.BauerM. (2020). Ketamine in the treatment of depressive episodes. Pharmacopsychiatry53, 45–50. 10.1055/a-0991-0582
65
RumpK.AdamzikM. (2022). Epigenetic mechanisms of postoperative cognitive impairment induced by anesthesia and neuroinflammation. Cells11, 2954. 10.3390/cells11192954
66
Sayan-OzacmakH.OzacmakV. H.TuranI.BarutF.HanciV. (2015). Pretreatment with remifentanil protects against the reduced-intestinal contractility related to the ischemia and reperfusion injury in rat. Braz J. Anesthesiol.65, 483–490. 10.1016/j.bjane.2013.09.007
67
ShenJ.FuG.JiangL.XuJ.LiL.FuG. (2013). Effect of dexmedetomidine pretreatment on lung injury following intestinal ischemia-reperfusion. Exp. Ther. Med.6, 1359–1364. 10.3892/etm.2013.1317
68
ShenJ.ZhanY.HeQ.DengQ.LiK.WenS.et al (2022). Remifentanil promotes PDIA3 expression by activating p38MAPK to inhibit intestinal ischemia/reperfusion-induced oxidative and endoplasmic reticulum stress. Front. Cell. Dev. Biol.10, 818513. 10.3389/fcell.2022.818513
69
ShenJ. T.LiY. S.XiaZ. Q.WenS. H.YaoX.YangW. J.et al (2016). Remifentanil preconditioning protects the small intestine against ischemia/reperfusion injury via intestinal δ- and μ-opioid receptors. Surgery159, 548–559. 10.1016/j.surg.2015.07.028
70
ShenX.DuJ.ZhaoY.GuanW. (2014). Phosphatase Wip1 as a new therapeutic target for intestinal ischemia-reperfusion injury. Expert Rev. Clin. Immunol.10, 1591–1595. 10.1586/1744666X.2014.975211
71
ShiY.ZhangX.WanZ.LiuX.ChenF.ZhangJ.et al (2022). Mesenchymal stem cells against intestinal ischemia-reperfusion injury: a systematic review and meta-analysis of preclinical studies. Stem Cell. Res. Ther.13, 216. 10.1186/s13287-022-02896-y
72
SridharanK.SivaramakrishnanG. (2019). Comparison of fentanyl, remifentanil, sufentanil and alfentanil in combination with propofol for general anesthesia: a systematic review and meta-analysis of randomized controlled trials. Curr. Clin. Pharmacol.14, 116–124. 10.2174/1567201816666190313160438
73
SunM.XieZ.ZhangJ.LengY. (2022). Mechanistic insight into sevoflurane-associated developmental neurotoxicity. Cell. Biol. Toxicol.38, 927–943. 10.1007/s10565-021-09677-y
74
VasileiouI.KalimerisK.NomikosT.XanthopoulouM. N.PerreaD.AgrogiannisG.et al (2012). Propofol prevents lung injury following intestinal ischemia-reperfusion. J. Surg. Res.172, 146–152. 10.1016/j.jss.2010.07.034
75
WalshC. T. (2022). Propofol: milk of amnesia. Cell.175, 10–13. 10.1016/j.cell.2018.08.031
76
WanJ.ShenC. M.WangY.WuQ. Z.WangY. L.LiuQ.et al (2021). Repeated exposure to propofol in the neonatal period impairs hippocampal synaptic plasticity and the recognition function of rats in adulthood. Brain Res. Bull.169, 63–72. 10.1016/j.brainresbull.2021.01.007
77
WangJ.ZhangW.WuG. (2021). Intestinal ischemic reperfusion injury: recommended rats model and comprehensive review for protective strategies. Biomed. Pharmacother.138, 111482. 10.1016/j.biopha.2021.111482
78
WuM.RoweJ. M.FlemingS. D. (2021). Complement initiation varies by sex in intestinal ischemia reperfusion injury. Front. Immunol.12, 649882. 10.3389/fimmu.2021.649882
79
WuM. B.MaB.ZhangT. X.ZhaoK.CuiS. M.HeS. C. (2020). Propofol improves intestinal ischemia-reperfusion injury in rats through NF-κB pathway. Eur. Rev. Med. Pharmacol. Sci.24, 6463–6469. 10.26355/eurrev_202006_21545
80
XiaoF.XiongL.WangQ.ZhouL.ZhouQ. (2012). Ketamine inhibits c-Jun protein expression in mouse hippocampus following cerebral ischemia/reperfusion injury. Neural Regen. Res.7, 833–836. 10.3969/j.issn.1673-5374.2012.11.006
81
XingW.ZhaoJ.LiuJ.LiuZ.ChenG. (2024). The protective effects of sevoflurane on subarachnoid hemorrhage. Med. Gas. Res.14, 1–5. 10.4103/2045-9912.379167
82
YangY.YiJ.PanM.HuB.DuanH. (2021). Edaravone alleviated propofol-induced neural injury in developing rats by BDNF/TrkB pathway. J. Cell. Mol. Med.25, 4974–4987. 10.1111/jcmm.16422
83
YasuharaH. (2005). Acute mesenteric ischemia: the challenge of gastroenterology. Surg. Today35, 185–195. 10.1007/s00595-004-2924-0
84
YiS.CaoH.ZhengW.WangY.LiP.WangS.et al (2023). Targeting the opioid remifentanil: protective effects and molecular mechanisms against organ ischemia-reperfusion injury. Biomed. Pharmacother.167, 115472. 10.1016/j.biopha.2023.115472
85
ZhangF. L.ChenX. W.WangY. F.HuZ.ZhangW. J.ZhouB. W.et al (2023b). Microbiota-derived tryptophan metabolites indole-3-lactic acid is associated with intestinal ischemia/reperfusion injury via positive regulation of YAP and Nrf2. J. Transl. Med.21, 264. 10.1186/s12967-023-04109-3
86
ZhangJ.LiuZ.LiuY.ShiY.ChenF.LengY. (2023a). Role of non-coding RNA in the pathogenesis of intestinal ischemia- reperfusion injury. Curr. Med. Chem.30, 4130–4148. 10.2174/0929867330666221219094145
87
ZhangQ.LiuX. M.HuQ.LiuZ. R.LiuZ. Y.ZhangH. G.et al (2021). Dexmedetomidine inhibits mitochondria damage and apoptosis of enteric glial cells in experimental intestinal ischemia/reperfusion injury via SIRT3-dependent PINK1/HDAC3/p53 pathway. J. Transl. Med.19, 463. 10.1186/s12967-021-03027-6
88
ZhangX.ZhouJ.HuQ.LiuZ.ChenQ.WangW.et al (2020). The role of janus kinase/signal transducer and activator of transcription signalling on preventing intestinal ischemia/reperfusion injury with dexmedetomidine. J. Nanosci. Nanotechnol.20, 3295–3302. 10.1166/jnn.2020.16416
89
ZhangX. K.ZhouX. P.ZhangQ.ZhuF. (2015). The preventive effects of dexmedetomidine against intestinal ischemia-reperfusion injury in Wistar rats. Iran. J. Basic Med. Sci.18, 604–609.
90
ZhangX. Y.LiuZ. M.WenS. H.LiY. S.LiY.YaoX.et al (2012). Dexmedetomidine administration before, but not after, ischemia attenuates intestinal injury induced by intestinal ischemia-reperfusion in rats. Anesthesiology116, 1035–1046. 10.1097/ALN.0b013e3182503964
91
ZhaoS.WuW.LinX.ShenM.YangZ.YuS.et al (2022). Protective effects of dexmedetomidine in vital organ injury: crucial roles of autophagy. Cell. Mol. Biol. Lett.27, 34. 10.1186/s11658-022-00335-7
92
ZhaoW.ZhouS.YaoW.GanX.SuG.YuanD.et al (2014). Propofol prevents lung injury after intestinal ischemia-reperfusion by inhibiting the interaction between mast cell activation and oxidative stress. Life Sci.108, 80–87. 10.1016/j.lfs.2014.05.009
Summary
Keywords
ischemia-reperfusion injury, anesthetic management, gas anesthetics, intravenous anesthetics, analgesics
Citation
Huang Z, Bai Y, Chen Y, Chen Y, Jiang Y and Zhou J (2024) Attenuation of intestinal ischemia-reperfusion-injury by anesthetics: a potentially protective effect of anesthetic management in experimental studies. Front. Pharmacol. 15:1367170. doi: 10.3389/fphar.2024.1367170
Received
08 January 2024
Accepted
08 February 2024
Published
20 February 2024
Volume
15 - 2024
Edited by
Magdalena Jasinska-Stroschein, Medical University of Lodz, Poland
Reviewed by
Ana Cristina Breithaupt-Faloppa, University of São Paulo, Brazil
Updates
Copyright
© 2024 Huang, Bai, Chen, Chen, Jiang and Zhou.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yuan Jiang, 85741920@qq.com; Jun Zhou, junzhou@swmu.edu.cn
† These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.